本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BEIJING, Oct. 18, 2025 /PRNewswire/ -- A news report from CRI Online Eager to secure a one-on-one consultation with admissions officers from Beijing's top universities? Wish to access the latest "Study in Beijing" policies and detailed program information in one go? The 2025 "Study in Beijing" Education Exhibition is set to make a grand debut in Vietnam and Indonesia. This event serves as an exclusive bridge connecting young scholars in both nations to China's exceptional educational resources, empowering them to realize their dreams of international academic advancement. Two Exhibitions, Tailored to Your Study-Abroad Needs Vietnam Stop:09:30-16:00, October 24, Đại Nam University.Detailed address: Second Teaching Building, Đại Nam University, No. 1, Xom Street, Phu Luong Ward, Hanoi City, Vietnam A comprehensive breakdown of the entire application process and specific admission policies for Vietnamese students. Indonesia Stop:09:30-16:00, October 26, Banquet Hall, Shangri-La Hotel Jakarta Detailed explanations of the "Study in Beijing" application procedures, scholarship opportunities, and career support services. Elite Institutions Gathered, Tailored to Southeast Asian Development Needs This exhibition brings together over 10 leading universities from Beijing, covering a wide range of high-demand disciplines — from business and science & technology, to languages and agriculture. These institutions are carefully selected to align with the academic interests and career aspirations of students in Vietnam and Indonesia: Tsinghua University, Peking University, Beijing Normal University, China Agricultural University, Communication University of China, North China Electric Power University, Beijing Foreign Studies University, Minzu University of China, Beijing Jiaotong University, University of Science and Technology Beijing, Capital Medical University, Beijing University of Chinese Medicine, Beijing University of Civil Engineering and Architecture, North China University of Technology, Beijing Technology and Business University, Beijing Polytechnic University, Beijing College of Finance and Commerce. Three Core Advantages to Smooth Your Path to Studying Abroad! Precision Alignment of Policies and Aspirations: Admissions officers will provide on-site interpretations of the 2025 "Study in Beijing" Special Scholarships. They will also shed light on admission preferences for highly sought-after disciplines like information technology and business, helping you overcome information asymmetries. Personalized Consultation: Based on your academic background and career goal, admissions teams can offer customized advice to help you find the most suitable institution and program. Immersive Experience of Chinese Education: Gain first-hand insights into the bilingual teaching systems and cross-cultural support services offered by Beijing's universities. Get a head start by experiencing campus environments virtually and planning your student life in advance. From Hanoi to Jakarta, the 2025 "Study in Beijing" Education Exhibition is committed to supporting you every step of the way! Mark your calendars: October 24 at Đại Nam University, Vietnam, and October 26 at Shangri-La Hotel Jakarta. Engage face-to-face with Beijing's top-tier universities and embark on your journey of international growth!
500名親子義工免費派發逾萬張旗紙 鼓勵市民「感講感受」 香港2025年10月18日 /美通社/ -- 宏利香港與香港情緒教育慈善機構JUST FEEL 感講 攜手籌辦全港首個「My旗日」，今日正式圓滿舉行。來自宏利及九所感講夥伴學校的 500 名親子義工，於全港各區邀請逾10,000 名市民選擇代表當下心情的旗紙並貼在身上，藉此鼓勵大眾認識及表達不同感受，好好關顧自己的情緒健康。 「My旗日」引入了創意概念，鼓勵市民從關心自己出發，用旗紙「說出」感受。活動上免費派發的感受旗紙，為今年初「My旗日」旗紙設計比賽的得獎作品，並由本地小學生精心設計，涵蓋開心、温暖、興奮、傷心、生氣及害怕共六款正、負面感受。市民透過將旗紙貼在身上，讓平日難以說出口的感受也能「被看見」，從而向公眾傳遞「感受無分對錯」的訊息。感受旗紙亦可成為啟發對話的契機，倡導大眾與身邊人透過互相分享，增進彼此的理解與關懷。 宏利與JUST FEEL 感講 自今年四月起建立長期策略慈善夥伴合作關係，旨在促進學生的情緒健康和培養同理心校園文化，並進一步推動宏利「全球影響力議程」(Impact Agenda) 的其中一項重要承諾——幫助大眾續享健康和福祉。「My旗日」作為重點項目之一，秉承宏利與JUST FEEL 感講 重視情緒健康的共同理念，由學校走到社區，向大眾推廣聆聽、接納和表達感受的重要性，避免壓抑情緒。與此同時，活動透過動員 500 名親子義工，讓這些家庭學習從感受出發，了解和關懷社區，從而促進親子交流及連結。 宏利香港及澳門首席市場總監林沛表示：「心理健康是整體健康的重要支柱，也是邁向優質人生的關鍵。宏利一直致力推動心理健康，這亦是我們幫助大眾續享健康和福祉的使命的重要一環。我們相信，建立更健康、更具韌性的社會需要讓大家有空間自在地表達和接納各種感受。我們很高興能夠與JUST FEEL 感講 合作，推出香港首個『My旗日』，這項有意義的活動旨在提升大眾對情緒健康的意識，並在社區中培養同理心與關愛精神。」 JUST FEEL 感講 共同創辦人暨執行總監楊思毅表示：「勇敢、真誠地說出感受，對於促進情緒健康，及建立健康的人際關係至關重要。感謝宏利及各所感講夥伴學校一直積極支持，並與我們同行，藉着今次『My旗日』，將情緒教育由校園拓展至家庭及社區。未來，我們會繼續與宏利緊密合作，於本地學校全方位推動善意溝通及社交情意教育，轉化學校和家庭的溝通文化，提升下一代的情緒健康。」 宏利與JUST FEEL 感講 舉辦全港首個「My旗日」，由500名親子義工於全港各區邀請10,000名市民選擇代表當下心情的旗紙並貼在身上，藉此鼓勵大眾認識及表達不同感受，好好關顧自己的情緒健康。 JUST FEEL 感講 共同創辦人暨執行總監楊思毅與宏利香港及澳門首席市場總監林沛親身支持「My旗日」活動，為親子義工打氣。 宏利及九所感講夥伴學校的親子義工積極參與活動，邀請市民分享當下感受，並送出各款感受旗紙。 宏利香港概覽： 宏利於香港開展業務超過125年，多年來一直深受信賴。自1897年在亞洲開業至今，宏利已發展成為香港主要金融服務機構之一，為香港及澳門超過 260 萬位客戶提供多元化的保障及財富管理產品和服務。我們致力於協助客戶輕鬆做出明智抉擇，實現精彩人生。 宏利香港透過宏利國際控股有限公司持有宏利人壽保險（國際）有限公司、宏利投資管理（香港）有限公司、宏利公積金信託有限公司。上述均為宏利金融有限公司的子公司。 宏利概覽： 宏利金融有限公司是全球領先的金融服務供應商，致力於幫助大眾輕鬆作出明智抉擇，實現精彩人生。本公司為個人、團體及企業提供理財建議及保險方案，全球總部位於加拿大多倫多，在加拿大、亞洲及歐洲以「宏利」的名稱營運，而在美國主要以「恒康」的名稱經營業務。通過「宏利財富與資產管理」，本公司為全球個人客戶、機構客戶以及退休計劃成員，提供全球性投資、理財建議及退休計劃服務。截至2024年底，本公司有超過37,000名員工、超過109,000名代理人，以及數以萬計的經銷合作夥伴，為超過3,600萬名客戶提供服務。本公司在多倫多、紐約及菲律賓證券交易所以股份代號MFC上市，在香港交易所則以股份代號945上市。 並非所有產品或服務在所有司法管轄區都可提供。詳情請瀏覽 manulife.com。 JUST FEEL 感講 概覽： JUST FEEL 感講 是全港首間於主流學校系統化推廣社交情意教育及善意溝通的慈善機構，奉行 「先處理心情，再處理事情」的格言，以轉化學校和家庭的溝通文化為願景，致力賦能教育工作者和家長，提升學生的身心靈健康。自 2018 年成立至今，JUST FEEL 感講 已與超過 65 所小學合作，為超過 55,300 位學生、8,900 位教師及 87,300 位家長提供支援。請瀏覽JUST FEEL 感講 網站：https://www.justfeel.hk/。
500 family volunteers distribute over 10,000 free flags to encourage the public to share their feelings HONG KONG, Oct. 18, 2025 /PRNewswire/ -- Manulife Hong Kong and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held the city's first-ever "My Flag Day" today. A total of 500 family volunteers from Manulife and nine of JUST FEEL's partner schools engaged with 10,000 citizens across the city, encouraging them to select a flag to wear, which would represent their current feelings. This initiative aims to raise public awareness of self-care by acknowledging and sharing different emotions. "My Flag Day" introduced a creative concept that encouraged individuals to focus on their own well-being and express their feelings through personalized flags. The Feeling Flags, which were distributed for free, were winning designs from the "My Flag Day" Flag Paper Design Competition held earlier this year. Illustrated by local primary school students, the flags represent six positive and negative feelings, including "happy", "warm", "excited", "sad", "angry", and "scared". By putting on these flags, people brought otherwise unspoken feelings into life, reinforcing the message that feelings are neither right nor wrong. These flags also served as conversation starters, inspiring people to share and, in turn, deepen mutual understanding and care. Since April 2025, Manulife and JUST FEEL have forged a multi-year strategic charity partnership to nurture students' emotional well-being and cultivate a "Compassionate School Culture". The collaboration also aligns with Manulife's Impact Agenda, underscoring the company's strong commitment to empowering sustained health and well-being within the community. As one of the flagship initiatives, "My Flag Day" brings this shared vision of emotional wellness beyond schools and into the public. It advocates for active listening, acceptance, and expression of feelings as a way to prevent emotional suppression. By mobilizing 500 family volunteers, Manulife and JUST FEEL also inspired families to explore feelings together, strengthen parent‑child relationships, and engage with their neighborhoods in more caring ways. "Mental well-being is a vital pillar of overall health and is essential to living a fulfilling life. At Manulife, we are committed to fostering mental wellness as part of our broader mission to empower sustained health and well-being. We believe that creating space for people to openly express and embrace all feelings is key to building a healthier, more resilient society. We are pleased to partner with JUST FEEL to launch Hong Kong's first 'My Flag Day' – a meaningful initiative that advances public awareness on emotional well-being and promotes empathy and compassion across our communities," said Celia Ling, Chief Marketing Officer of Manulife Hong Kong and Macau. "Expressing our feelings with courage and sincerity is crucial for fostering well-being and building healthy relationships. We are grateful to Manulife and our partner schools for their continuous support and for joining us on this journey. Through 'My Flag Day', we have extended emotional education from schools to families and the wider community. Looking ahead, we will continue to work closely with Manulife to promote compassionate communication and social‑emotional learning across local schools, transforming the communication culture in schools and families, thereby enhancing students' emotional well-being," said Raymond Yang, Co-founder and Executive Director of JUST FEEL. Manulife and JUST FEEL, a Hong Kong-based NGO dedicated to emotional education, successfully held Hong Kong's first-ever "My Flag Day" today. Five hundred family volunteers engaged with 10,000 citizens across the city, encouraging them to select a flag to wear, which would represent their current feelings. This initiative calls for public awareness of self-care by acknowledging and sharing different feelings. Raymond Yang, Co-founder and Executive Director of JUST FEEL, and Celia Ling, Chief Marketing Officer, Manulife Hong Kong and Macau, joined My Flag Day to cheer for the volunteers. The family volunteers from Manulife and nine JUST FEEL partner schools invited the public to share their feelings and actively distributed the Feeling Flags. About Manulife Hong KongManulife Hong Kong has been a trusted name for more than 125 years. Since our operations started in Asia in 1897, we have grown to become one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers. Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation. About ManulifeManulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com. About JUST FEELJUST FEEL is the first charity to systematically promote Compassionate Communication and Social-Emotional Learning in local schools in Hong Kong. With the motto of "Connection before Solution", JUST FEEL is dedicated to transforming the communication culture in schools and families, empowering educators and parents to enhance the emotional well-being of children. Since its establishment in 2018, JUST FEEL has collaborated with over 65 primary schools, supporting over 55,300 students, 8,900 teachers, and 87,300 parents. For additional information, please visit https://www.justfeel.hk/.
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: KN026-001, also known as KC-WISE), have been presented at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) Late-Breaking Abstract (LBA) Oral Presentation Session. LBA Oral Presentation Session is a highly anticipated global highlight of the ESMO Congress. The research presented in this category is both highly topical and of significant clinical value. Their findings often herald potential impacts on current clinical practice and can even guide the future direction of entire therapeutic fields. Title：KN026 in combination with chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Interim analysis of KC-WISENumber: LBA 78Speaker: Jianming Xu, Chinese PLA General HospitalDate：Friday, 17 October 2025 METHODS Enrolled patients in study KN026-001 (KC-WISE) with HER2-positive GC/GEJ who had disease progression after trastuzumab-based therapy were randomized to receive either anbenitamab (KN026) in combination with chemotherapy (the "Anbenitamab Group") or chemotherapy with placebo (the "Control Group"). The patients were stratified based on (i) type of chemotherapy, (ii) HER2 expression level, and (iii) number of prior lines of treatments. RESULTS At baseline, patient characteristics were generally well balanced between the two groups. The median age was approximately 64 in the Anbenitamab Group and 61 in the Control Group. In both groups, over 80% of patients had an ECOG PS of 1, and nearly all patients were diagnosed with stage IVB disease at enrollment. All patients had previously received chemotherapy, most commonly taxanes (over 70%), with the remainder receiving irinotecan-based regimens. As of April 3, 2025, the median follow-up duration was 9.7 months (95% CI, 7.2 to 11.9 months) in the Anbenitamab Group and 9.8 months (95% CI, 7.4 to 12.9 months) in the Control Group. Efficacy as assessed by the Independent Review Committee (IRC): The median treatment-related adverse event (PFS) for the Anbenitamab Group was 7.1 months, compared with 2.7 months in the Control Group. The hazard ratio (HR) is 0.25 (P value is 5.44 × 10⁻¹²), corresponding to a 75% reduction in the risk of disease progression or death. The median overall survival (OS) for the Anbenitamab Group was 19.6 months (not mature), compared with 11.5 months in the Control Group. The HR is 0.29, representing a 71% reduction in the risk of death, and P value is 1.56 × 10⁻6, which is well below the prespecified extremely stringent alpha threshold of 0.00001. The objective response rate (ORR) was 55.8% in the Anbenitamab Group versus 10.8% in the Control Group, while the disease control rate (DCR) was 80.0% and 41.9%, respectively. The median duration of response (DoR) was 8.2 months and 2.9 months, respectively. Safety: The median treatment duration was 6.5 cycles in the Anbenitamab Group and 3.0 cycles in the Control Group. The incidence of Grade 3 treatment-emergent adverse events (TEAEs) or above was 60.6% in the Anbenitamab Group and 51.6% in the Control Group, while the incidence of serious adverse events (SAEs) was 31.9% and 33.3%, respectively. The most frequently observed Grade 3 treatment-related adverse events (TRAEs) or above in the Anbenitamab Group included neutropenia (29.8%), leukopenia (21.3%), anemia (18.1%), diarrhea (8.5%) and asthenia (8.5%), while the most frequently observed Grade 3 TRAEs or above in the Control Group included leukopenia (24.7%), neutropenia (21.5%), anemia (10.8%), diarrhea (7.5%) and thrombocytopenia (5.4%). The incidence of cardiotoxicity in both groups were both 3.2%, indicating fewer cardiac concerns. CONCLUSIONS The interim analysis demonstrated that anbenitamab achieved superior efficacy in second-line or third-line HER2-positive gastric cancer patients who had been previously treated with trastuzumab. The study met both its primary endpoints of PFS and OS with statistically significant and clinically meaningful improvements, indicating its potential to change clinical practice guidelines for the treatment of second-line or above gastric cancer. Compared with the recently published DESTINY-Gastric04 results of DS-8201 in second-line gastric cancer, anbenitamab demonstrates potential advantages in both efficacy and safety. Prompted by these encouraging results of anbenitamab, we are preparing to expand clinical development into first-line and perioperative gastric cancer through new registrational trials, aiming to extend benefits to more patients. Meanwhile, JSKN003, an ADC built upon KN026, has demonstrated high-security profile and distinctive advantages. With multiple registrational studies currently advancing as planned, we anticipate even more outstanding performance from JSKN003 in the future. About Anbenitamab (KN026) Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Results from multiple clinical studies showed that KN026 has promising efficacy for the treatment of HER2-positive solid tumors, both in the first-line and in patients previously treated with trastuzumab. Currently, several pivotal trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive BC, neoadjuvant treatment of HER2-positive BC are being conducted. KN026 for the treatment of patients with HER2-positive GC who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA). KN026 for the treatment of HER2-positive or low expressing GC was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the NMPA for use in combination with chemotherapy in patients with HER2-positive locally advanced, recurrent, or metastatic GC/GEJ who have failed at least one prior systemic therapy (which must include trastuzumab in combination with chemotherapy). In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan). About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK). Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies. One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
WUHU, China, Oct. 18, 2025 /PRNewswire/ -- A clear and composed "Hello everyone, I'm Mornine" ignited the climax of the 2025 Chery Global Innovation Conference. This unique "presenter" was none other than AiMOGA robot Mornine. In a ten-minute fully autonomous presentation, she reviewed AiMOGA's journey from concept to real-world deployment across more than 30 countries and demonstrated multilingual interaction and scenario-based applications, outlining a vivid vision of "car-machine collaboration." AiMOGA Robot “Mornine” on stage at the Innovation Conference Mornine's remarkable appearance became a vivid illustration of the conference theme, "Innovation • Intelligence Leading the World." As one of the core activities of the 2025 Chery International User Summit, the Innovation Conference brought together academicians, top global experts, industry leaders, media, and partners to witness Chery's breakthrough transformation toward a full-scenario intelligent ecosystem. From Presenter to Experience Officer: A Robot's Ecosystem Showcase Mornine's highlights extended beyond the main stage. In the outdoor demonstration area, her "multi-agent collaboration" became another focus of attention. From professional introductions and vehicle guidance to door-opening demonstrations, every step was completed autonomously. With the coordination of her vision-tactile dexterous hand and multi-expression interaction system, Mornine impressed visitors with fluent demonstrations—pouring water, opening car doors, and other signature actions that drew rounds of applause. Dr. Gao Xinhua delivers a keynote presentation Dr. Gao Xinhua, CTO of Chery Group, stated during his keynote: "Our technology evolution is expanding from 'wheels' to a 'three-dimensional ecosystem,' and intelligent robots are a natural extension of this strategy." This vision is reflected in AiMOGA's technical details: its ±5 cm precision autonomous navigation and dynamic obstacle avoidance builds on Chery's achievements in intelligent driving; and its 17-degree-of-freedom vision-tactile dexterous hand integrates Chery's electromechanical and control system expertise. The Strength of "Tech Chery": Five Domains of Breakthrough Innovation Behind AiMOGA's impressive performance lies the technological foundation of "Tech Chery." At this year's Innovation Conference, Chery unveiled major breakthroughs across five key technology domains, releasing more than ten world-leading innovations. The new Kunpeng engine set a new global benchmark with over 48% thermal efficiency; the high-energy solid-state battery achieved 600 Wh/kg, near the theoretical lithium limit; the Luoshu AI large model covers 1,000+ vehicle control functions, with response time <1000 ms and task accuracy >95%; the Falcon 900 intelligent driving system integrates VLA and world modeling, targeting L3–L4 autonomous driving with full safety redundancy. From leading hybrid performance to human-centered intelligent interaction, from key breakthroughs to full-ecosystem development, Chery is transforming its 28 years of technological expertise into a key to the future — opening a new era of global intelligent mobility. From Wuhu to the World: A New Global Identity for the Future Just before the conference, AiMOGA Robotics achieved a series of EU certifications, becoming the world's first robot to complete both hardware and software compliance. This milestone marks a new chapter in Chery's global ecosystem — from Poland to Malaysia, Indonesia to South Africa, AiMOGA Dedicated To Embodied Intelligence. Be Committed To Building World-Leading And Trusted AI Assistants. Behind this growing global footprint lies AiMOGA's powerful R&D network — spanning Shanghai, Europe, and North America, and collaborating with top universities. This multidimensional R&D ecosystem fuels AiMOGA's ongoing evolution and serves as a strong foundation for Chery's global innovation strategy. AiMOGA Robot interactive experience zone outside the venue From AiMOGA Robotics leading the era of embodied intelligence to Chery's progress across five technological frontiers, a new vision of intelligent mobility is emerging. Within this ecosystem, robots have become the natural bridge between people, vehicles, and services. From showrooms to city blocks, from production lines to living spaces, Chery is building a future where humans and robots coexist harmoniously and technology integrates seamlessly with real-world scenarios. At this moment, on the stage of the 2025 Chery Global Innovation Conference, we are witnessing not just a product release, but the beginning of a new era. Looking ahead, Chery will continue to drive innovation and speak the language of intelligence, joining global partners to usher in a new era of human-robot symbiosis and intelligent connectivity.
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025. This ongoing first-in-human trial evaluates the safety, tolerability and preliminary efficacy of SCG142, a novel human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T) cell therapy armoured with a TGFβRII-41BB chimeric switch receptor. Eligible patients are HLA-A*02:01-positive with advanced HPV16- or HPV52-positive carcinomas who have progressed on or were intolerant to at least one prior systemic therapy. Key endpoints include safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. As of the data cut-off, tumor shrinkage was observed in all seven treated patients, resulting in a disease control rate (DCR) of 100%. Four of the seven patients (57%) achieved >30% tumor reduction, including two confirmed partial responses (PR) and two unconfirmed PRs. No dose-limiting toxicities or serious adverse events were reported. These preliminary findings support continued clinical development of SCG142. "SCG142 is a novel and differentiated HPV-specific TCR T cell therapy with promising clinical activity." said Prof. Dr. Yang Li, Director of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University. "We're excited that tumor shrinkage was observed in all seven treated patients and that SCG142 was well tolerated. These encouraging preliminary findings underscore the potential of SCG142 to provide new solutions for patients in a variety of HPV16 and HPV52 expressing cancers and support further evaluation in larger patient cohorts", she added. SCG142 was isolated with GianTCRTM, SCG's proprietary TCR screening platform with the ability to identify fully natural TCRs with high affinity and high avidity properties as well as potent antiviral and anti-tumor effects against infection-related solid tumors accompanied by a lower risk of off-target toxicity. "We are delighted that the excellent preclinical profile of our HPV-E7-specific TCR - including high avidity and dual functionality in both CD8+ and CD4+ T cells - has translated into clinical activity with SCG142" added Dr. Susanne Wilde, VP, Head of Preclinical Research of SCG Cell Therapy. Besides SCG142, SCG is also advancing SCG101, a hepatitis B virus (HBV)-specific TCR T cell therapy for the treatment of HBV-related hepatocellular carcinoma (HCC). – END – About Human Papillomavirus and Cancers Human papillomavirus (HPV) infection is the most common sexually transmitted infection. Nearly all sexually active people are infected with HPV and around half of these infections occur with a high-risk HPV type, which can lead to cancer development.1 As such, HPV infection accounts for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and 60% of penile and oropharyngeal cancers, and it causes an estimated 690,000 cancers worldwide each year[1],[2]. About SCG Cell Therapy SCG is a leading biotechnology company focusing on the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: HPV, HBV and EBV, and develops a broad and unique pipeline of TCR-based cellular immunotherapy products against infection- associated cancers. With the proprietary GianTCRTM TCR screening platform, in house viral vector production and AutoCellTM, a fully closed, automatic and low-cost cell therapy manufacturing system, the company covers the entire value chain from new target research and discovery, manufacturing, and clinical development. For more information about SCG, please visit us at www.scgcell.com. [1] HPV and cancer. National Cancer Institute. (2025, May 9) [2] Basic information about HPV and cancer. Centers for Disease Control and Prevent (2024, September 17）
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
